Parenteral Nutrition Monitoring
Key Points
- Parenteral nutrition is used when the GI tract cannot safely absorb nutrients.
- PN requires strict infusion accuracy and line-care safety, often via central access.
- Monitoring focuses on infection risk, glycemic/metabolic trends, fluid status, and liver/renal tolerance.
- PPN is typically short-term support (often under about 10 days), whereas TPN is used for broader long-term replacement needs.
- Because TPN has high osmolality, peripheral infusion is generally avoided due to phlebitis and thrombosis risk.
- For newly placed central PN lines, verify chest imaging confirms tip position and no insertion-related pneumothorax.
- Abrupt TPN discontinuation can precipitate hypoglycemia and requires controlled weaning or transition per order.
Pathophysiology
Parenteral nutrition bypasses GI processing and delivers nutrients intravascularly. This supports nutrition in severe GI dysfunction but raises risk for catheter-related infection and metabolic complications if monitoring is inadequate.
Because PN solutions are highly concentrated, central venous access is commonly required to reduce vascular irritation risk. Formulations include dextrose, amino acids, and lipid emulsions plus electrolytes, vitamins, and trace minerals. In critical illness with high catabolic stress, protein/amino-acid support is a key strategy to limit muscle-wasting progression when enteral intake is not feasible.
Classification
- PPN: Short-term supplementation (commonly under about 10 days), often delivered through PICC-based central-tip access with lower-osmolality strategy per protocol.
- TPN: Full nutrition replacement via central venous access, typically denser and appropriate for longer-term therapy.
- Infusion formats: Two-in-one and three-in-one admixtures based on facility protocol.
- Central-access formats: Nontunneled central lines for shorter episodes, tunneled lines for longer durations, and PICC lines for intermediate-duration therapy.
- Common indication contexts: Paralytic ileus, prolonged postoperative bowel dysfunction, severe malnutrition, major burns, advanced cancer, liver failure, or pregnancy-associated hyperemesis when enteral feeding is not feasible.
- Common contraindication contexts: Intestinal obstruction/perforation requiring different acute strategy, significant hepatic or renal impairment requiring individualized risk review, and uncontrolled diabetes until metabolic control is stabilized.
Nursing Assessment
- Assess central-line status, dressing integrity, and CLABSI risk cues.
- For newly placed central lines used for PN, confirm documented post-insertion chest X-ray review before first infusion.
- Assess blood glucose, electrolytes, and protein markers per monitoring schedule.
- Include trend review of CBC, BUN, albumin, and prealbumin when ordered to evaluate tolerance and nutrition response.
- Assess fluid-balance trend (edema, I/O, daily weights) and end-organ tolerance.
- Assess for signs of nutrient excess and metabolic intolerance during ongoing PN therapy.
- Track intake and output at least every 12 hours in unstable initiation phases unless local protocol sets a shorter interval.
- Monitor urine glucose and capillary glucose frequently during initiation and titration (commonly every 8 hours or more often per order/policy).
- If PN is infused peripherally, monitor the site frequently for infiltration and treat infusion interruption as hypoglycemia risk until access is re-established.
Nursing Interventions
- Use dedicated line and pump safeguards for PN infusion.
- Use strict aseptic line-access technique, including hand hygiene, hub disinfection, and sterile tubing replacement for each new PN bag per policy.
- Perform ordered lab surveillance and respond quickly to abnormal trends.
- Track common complication clusters: central-line infection, fluid overload, glycemic/electrolyte instability, and hepatobiliary intolerance.
- Maintain sterile line-care technique and tubing-change schedule per policy.
- Coordinate with pharmacy/dietetics to adjust composition based on response.
- Do not infuse high-osmolality TPN through peripheral lines; escalate for central access when required.
- If peripheral PN infiltrates, stop infusion, re-establish access promptly per protocol, and monitor/treat interruption-related hypoglycemia risk.
- Avoid abrupt discontinuation; taper or transition to alternate carbohydrate support per order to reduce rebound hypoglycemia risk.